Tone mix
Week by week 52 weeks
Share of Neurocrine Biosciences Inc's 191 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 28, 2026 · tone -100UBS Group Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price-121
- Week of Jan 5, 2026 · tone +98Analysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Target Price at $175.25+71
- Week of Oct 20, 2025 · tone +100Neurocrine Biosciences Announces Positive Data From Post-Hoc Analysis Of Tardive Dyskinesia Study+67
- Week of Oct 19, 2026 · tone +92Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome+66
- Week of Sep 29, 2025 · tone +99Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $160.26 Consensus Price Target from Brokerages+59
- Week of Jun 1, 2026 · tone +100RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)+52
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Neurocrine Biosciences Inc in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | +46 |
| Last 30 sessions | 11 | +8 |
| Last 90 sessions | 61 | +37 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 3 outletsWhere Will Neurocrine Biosciences Be in 5 Years?Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Where Will Neurocrine Biosciences Be in 5 Years? | www.fool.com | 3 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +92: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletNeurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome | www.prnewswire.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.tickerreport.com · 1 outletNeurocrine Biosciences' (NBIX) Buy Rating Reiterated at Needham & Company LLCPositive
- www.prnewswire.com · 1 outletNeurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at Needham & Company LLC | www.tickerreport.com | 1 | Positive |
| Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.insidermonkey.com · 1 outletAxsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? | www.insidermonkey.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial ResultsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Neurocrine Biosciences Inc, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.